Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology

4278 - Efficacy and safety of Vandetanib for patients with advanced and progressive medullary thyroid cancer (MTC) as systemic treatment beyond first-line therapy.


21 Oct 2018


Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology


Cytotoxic Therapy

Tumour Site

Thyroid Cancer


Jorge Hernando Cubero


Annals of Oncology (2018) 29 (suppl_8): viii467-viii478. 10.1093/annonc/mdy293


J. Hernando Cubero1, E. Grande2, P. Jimenez Fonseca3, C. Villabona4, J.M. Trigo Perez5, J. Martinez Trufero6, I. Pajares Bernad7, C. Lopez8, T. Alonso9, J. Biarnes10, T. Ramón Y Cajal11, M. Duran12, J.J. Grau13, S. Arevalo Lobera14, R. Mesia Nin15, M. Llanos16, E. Dalmau Portulas17, C. Alvarez18, C. Zafon19, J. Capdevila Castillon1

Author affiliations

  • 1 Medical Oncology, Vall d'Hebron University Hospital, 08035 - Barcelona/ES
  • 2 Head Of Medical Oncology Department, MD Anderson Cancer Center Center Espana, 28033 - Madrid/ES
  • 3 Medical Oncology, Hospital Universitario Central de Asturias, 33006 - Oviedo/ES
  • 4 Medical Oncology, Hospital Universitario de Bellvitge, 08907 - Barcelona/ES
  • 5 Medical Oncology, Hospital Universitario Virgen de la Victoria, 29010 - Málaga/ES
  • 6 Medical Oncology Department, Hospital Miguel Servet, 50009 - Zaragoza/ES
  • 7 Medical Oncology, Hospital Miguel Servet, 50009 - Zaragoza/ES
  • 8 Medical Oncology, Marques de Valdecilla University Hospital, Santander/ES
  • 9 Medical Oncology, Hospital Ramón y Cajal, 28034 - Madrid/ES
  • 10 Medical Oncology, Hospital Universitario Doctor Josep Trueta, Gerona/ES
  • 11 Breast Cancer, Hospital de la Santa Creu i Sant Pau, 08041 - Barcelona/ES
  • 12 Medical Oncology, Hospital Universitario Rey Juan Carlos, Madrid/ES
  • 13 Medical Oncology, Hospital Clinic y Provincial de Barcelona, 8036 - Barcelona/ES
  • 14 Medical Oncology, Hospital Donostia, 20014 - San Sebastian/ES
  • 15 Medical Oncology, Catalan Institute of Oncology (ICO Badalona), Hospital Germans Trias i Pujol, 08916 - Badalona/ES
  • 16 Medical Oncology, Hospital Universitario de Canarias, Santa Cruz de Tenerife/ES
  • 17 Medical Oncology, Hospital de Sabadell Corporacis Parc Tauli, 8208 - Sabadell/ES
  • 18 Medical Oncology, Hospital Universitario La Paz, Madrid/ES
  • 19 Endocrinology, Vall d'Hebron University Hospital, 08035 - Barcelona/ES


Login to access the resources on OncologyPRO.

If you do not have an ESMO account, please create one for free.

Abstract 4278


Vandetanib has demonstrated efficacy in advanced MTC in a large phase III trial (ZETA trial, JCO 2012). However, the study had several limitations that impact in the daily clinical practice, such as the efficacy in patients (pts) with documented disease progression or beyond first-line therapy who have a worse prognosis.


Pts with advanced unresectable MTC with previous radiologically documented disease progression were included in the Spanish National Database of the Rare Cancer Working Group (GETHI). Pts started treatment with vandetanib 300mg qd as initial dose, with dose reductions allowed as per toxicity. Baseline characteristics, progression free survival (PFS), response rate (RR), correlation with biomarkers and toxicity data were reviewed retrospectively in first, second and third line setting. The program was validated by regulatory authorities and all patients signed and informed consent form.


59 pts (med age:48y; male 61%) were included. 14% had RET mutations. Vandetanib was given as first line in 61%, second-line in 22% and third-line therapy in 17% of pts. RR and median PFS in first, second and third-lines were 47%, 53% and 40% (p 0.85%) and 16.8, 13.6 and 11.5 months (p 0.94) respectively. No correlation was found between calcitonin or CEA reduction and RR. However, CEA level decrease (30% versus baseline) appeared to predict PFS longer than 11 months (p 0.028). Treatment was well tolerated and dose reduction was needed in 23% to handle toxicity. Main side effects were grade 1-2 including fatigue (22%), skin rash (19%), hypertension (14%) and diarrhea (14%). Most frequent grade 3 toxicity was oral mucositis (3%).


Probability of tumor shrinkage with vandetanib is maintained throughout treatment lines despite of a trend of reduced benefit in PFS beyond first-line in a cohort of pts with a worse prognosis. CEA reduction may predict longer PFS. Safety is maintained regardless prognosis and prior therapies.

Clinical trial identification

Legal entity responsible for the study

Spanish Rare Cancer Working Group (GETHI).


Has not received any funding.

Editorial Acknowledgement


All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.